secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001213900-24-015329
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Helix Acquisition Corp. II completes $184M IPO and $5M private placement; trust funded
--------------------------------------------------------------------------------

- IPO of 18.4M Class A shares at $10.00 each included full exercise of 2.4M over-allotment shares.
- Private sale of 509,000 Class A shares to sponsor Helix Holdings LLC at $10.00/share, gross $5.09M.
- Net proceeds of $184M (including $5.52M deferred underwriting fee) deposited into trust account.
- Audited balance sheet at Feb 13, 2024: $184M in trust, $2.5M cash, $3.2M shareholders' deficit.
- SPAC focused on healthcare; must complete initial business combination within 24 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000121390024015329/0001213900-24-015329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000121390024015329/ea0200237-8k_helixacq2.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-015329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer